In3Bio is an innovation driven biotech company with a broad R&D platform of novel therapeutics that offer potential treatment for multiple cancers

Our Story

In3Bio is a privately held biotechnology company based in the UK. Established in 2010, In3Bio’s innovation-driven program is dedicated to new therapeutics that can provide cancer patients new and effective treatments with emphasis on tolerability.

Technology

Our technology and approach enable the development of novel biologics that affect multiple signalling pathways overactive in cancer.

News & Publications

Publications

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.

Read More →
News

IN3BIO gains approval for Phase I/II clinical trial

Read More →
Publications

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells

Read More →

Science

We develop novel well-tolerated therapeutics that enrich Precision Medicine and combat drug resistance. Our translational research program spans design, production, pre-clinical and clinical efficacy testing, endorse indications and scrutinise combination strategies.

Development

We have advanced pre-clinical and clinical R&D of versatile biologics that facilitate immunotherapy by targeting cancer-dominating growth factors.

Tolerability

We develop therapeutics that create a new standard of tolerability in cancer treatment without increasing toxicity burden.

Combination

We continue to improve our therapeutics with high efficacy, less toxicity and help resistance in combination strategies of market demand

Collaborative Research Efforts

Our R&D network include facilities located in Belgium, France, Scotland (UK), Spain and Malaysia.

Pipeline

We have an assorted pipeline, covering a cancer-focused portfolio of growth factor biologics.

Technology Platform

With the unique technology platform we are able to create pipelines that target different types of growth factors to treat various solid tumours

Pipeline

Single Target Molecule

Synthetic protein molecules (biologics) are designed, produced and tested. They resemble specific growth factors that play crucial roles in cancer development and progression (tumorigenesis and metastasis).

They function as vaccines, i.e. induce specific antibody responses towards the selected target growth factor.

Bi-Specific Molecule

Bispecific recombinant proteins are designed to resemble two growth factors in chimeric or fused form. Upon vaccination they enable induction of specific antibody responses towards the two target growth factors.

Patents

Our protection of IP includes the United States, Europe, Japan, China, Australia and other countries.

We work with patent attorneys in the US (Boston) and the UK (London) to draft out global patent strategies for each invention. This interactive process ensures adequate and effective protection of our IP rights and their commercial value, enabling us to stay competitive.

Read More

Copyright 2020 In3Bio Group of Companies
All rights reserved.